The role of radiation therapy and systemic treatments in meningioma: The present and the future

Meningiomas are the most prevalent tumors of the central nervous system. Their standard treatment is surgery, which can be curative. Adjuvant radiotherapy treatment is reserved for newly diagnosed cases of grade II and grade III meningiomas in cases of recurrent disease or when surgery is not radical or feasible. However, around 20% of these patients cannot undergo further surgical and/or radiotherapy treatment. Systemic oncological therapy can find its place in this setting. Several tyrosine kinase inhibitors have been tested (gefitinib, erlotinib, sunitinib) with unsatisfactory or negative results. Bevacizumab has shown encouraging results in these settings of patients. Immunotherapy with immune checkpoint inhibitors has reported interesting results with modest objective response rates. Several ongoing studies are assessing different target therapies and multimodal therapies; the results are to be disclosed. Not only a better understanding of the molecular characteristics in meningiomas has allowed the gathering of more information regarding pathogenesis and prognosis, but in addition, the availability of new target therapy, immunotherapy, and biological drugs has widened the scope of potentially effective treatments in this patient population. The aim of this review was to explore the radiotherapy and systemic treatments of meningioma with an analysis of ongoing trials and future therapeutic perspectives.

[1]  P. Brastianos,et al.  Emerging systemic treatment options in meningioma , 2022, Journal of Neuro-Oncology.

[2]  G. Umana,et al.  The Long and Winding Road: An Overview of the Immunological Landscape of Intracranial Meningiomas , 2022, Cancers.

[3]  J. Honegger,et al.  The Current Role of Peptide Receptor Radionuclide Therapy in Meningiomas , 2022, Journal of clinical medicine.

[4]  A. Giobbie-Hurder,et al.  Phase 2 study of pembrolizumab in patients with recurrent and residual high-grade meningiomas , 2022, Nature Communications.

[5]  J. Pichler,et al.  Trabectedin for recurrent WHO grade 2 or 3 meningioma: a randomized phase 2 study of the EORTC Brain Tumor Group (EORTC-1320-BTG). , 2021, Neuro-oncology.

[6]  T. Batchelor,et al.  Diagnostic, therapeutic, and prognostic implications of the 2021 World Health Organization classification of tumors of the central nervous system , 2021, Cancer.

[7]  J. Barnholtz-Sloan,et al.  CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014-2018. , 2021, Neuro-oncology.

[8]  G. Reifenberger,et al.  The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. , 2021, Neuro-oncology.

[9]  M. Weller,et al.  EANO guideline on the diagnosis and management of meningiomas. , 2021, Neuro-oncology.

[10]  Raymond Y Huang,et al.  Activity of PD-1 blockade with Nivolumab among patients with recurrent atypical/anaplastic meningioma: Phase II trial results. , 2021, Neuro-oncology.

[11]  M. Zuccarello,et al.  Neurofibromatosis Type 2 (NF2) and the Implications for Vestibular Schwannoma and Meningioma Pathogenesis , 2021, International journal of molecular sciences.

[12]  K. Wei,et al.  Treatment of intracranial meningioma with single-session and fractionated radiosurgery: a propensity score matching study , 2020, Scientific Reports.

[13]  A. Duun-Henriksen,et al.  Somatostatin Receptor–Targeted Radiopeptide Therapy in Treatment-Refractory Meningioma: Individual Patient Data Meta-analysis , 2020, The Journal of Nuclear Medicine.

[14]  David T. W. Jones,et al.  CDKN2A/B homozygous deletion is associated with early recurrence in meningiomas , 2020, Acta Neuropathologica.

[15]  B. Parfait,et al.  Validation of a scoring system to evaluate the risk of rapid growth of intracranial meningiomas in neurofibromatosis type 2 patients. , 2020, Journal of neurosurgery.

[16]  S. Spiegl-Kreinecker,et al.  Poor prognosis associated with TERT gene alterations in meningioma is independent of the WHO classification: an individual patient data meta-analysis , 2020, Journal of Neurology, Neurosurgery, and Psychiatry.

[17]  M. Sanson,et al.  Everolimus and Octreotide for Patients with Recurrent Meningioma: Results from the Phase II CEVOREM Trial , 2020, Clinical Cancer Research.

[18]  J. Lemée,et al.  Benefits of re-do surgery for recurrent intracranial meningiomas , 2020, Scientific Reports.

[19]  D. Georg,et al.  Bringing Europe together in building clinical evidence for proton therapy – the EPTN–ESTRO–EORTC endeavor , 2019, Acta oncologica.

[20]  B. Coche-Déquéant,et al.  Hypofractionated Stereotactic Radiotherapy for Patients with Intracranial Meningiomas: impact of radiotherapy regimen on local control , 2018, Scientific Reports.

[21]  Johannes A Langendijk,et al.  Radiation dose constraints for organs at risk in neuro-oncology; the European Particle Therapy Network consensus. , 2018, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[22]  J. Debus,et al.  Evaluation of particle radiotherapy for the re-irradiation of recurrent intracranial meningioma , 2018, Radiation oncology.

[23]  S. Santagata,et al.  Uncovering the links between systemic hormones and oncogenic signaling in the pathogenesis of meningioma. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  S. Santagata,et al.  BAP1 mutations in high-grade meningioma: implications for patient care. , 2017, Neuro-oncology.

[25]  Martin Sill,et al.  DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. , 2017, The Lancet. Oncology.

[26]  C. Mawrin.  Animal models of meningiomas. , 2017, Chinese clinical oncology.

[27]  R. Beroukhim,et al.  Genomic landscape of high-grade meningiomas , 2017, Journal of Neurological Surgery Part B: Skull Base.

[28]  Jeong Hoon Kim,et al.  Analysis of the results of recurrent intracranial meningiomas treated with re-radiosurgery , 2017, Clinical Neurology and Neurosurgery.

[29]  M. Mehta,et al.  High-risk meningioma: Initial outcomes from NRG Oncology/RTOG 0539. , 2016, International journal of radiation oncology, biology, physics.

[30]  P. Cornu,et al.  Grade II meningiomas and Gamma Knife radiosurgery: analysis of success and failure to improve treatment paradigm. , 2016, Journal of neurosurgery.

[31]  M. Meyerson,et al.  Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas , 2016, Neuro-oncology.

[32]  Mark W. Youngblood,et al.  Recurrent somatic mutations in POLR2A define a distinct subset of meningiomas , 2016, Nature Genetics.

[33]  J. Hainsworth,et al.  A phase II trial of bevacizumab and everolimus as treatment for patients with refractory, progressive intracranial meningioma , 2016, Journal of Neuro-Oncology.

[34]  M. McDermott,et al.  Surgical Resection and Interstitial Iodine-125 Brachytherapy for High-Grade Meningiomas: A 25-Year Series , 2016, Neurosurgery.

[35]  G. Reifenberger,et al.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary , 2016, Acta Neuropathologica.

[36]  K. Aldape,et al.  TERT Promoter Mutations and Risk of Recurrence in Meningioma. , 2016, Journal of the National Cancer Institute.

[37]  R. Beroukhim,et al.  Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma. , 2016, Neuro-oncology.

[38]  J. Kresak,et al.  Neurofibromatosis: A Review of NF1, NF2, and Schwannomatosis , 2016, Journal of Pediatric Genetics.

[39]  D. Brachman,et al.  Intermediate-risk meningioma: initial outcomes from NRG Oncology RTOG 0539. , 2015, Journal of neurosurgery.

[40]  M. Levivier,et al.  The Role of Mifepristone in Meningiomas Management: A Systematic Review of the Literature , 2015, BioMed research international.

[41]  R. Beroukhim,et al.  ARID1A and TERT promoter mutations in dedifferentiated meningioma. , 2015, Cancer genetics.

[42]  O. Chinot,et al.  Combined treatment by octreotide and everolimus: Octreotide enhances inhibitory effect of everolimus in aggressive meningiomas , 2015, Journal of Neuro-Oncology.

[43]  M. Smith.  Germline and somatic mutations in meningiomas. , 2015, Cancer genetics.

[44]  Katrina H. Smith,et al.  Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma , 2015, Neurology.

[45]  R. Hevner,et al.  Germline SMARCE1 mutations predispose to both spinal and cranial clear cell meningiomas , 2014, The Journal of pathology.

[46]  J. Nault,et al.  High Incidence of Activating TERT Promoter Mutations in Meningiomas Undergoing Malignant Progression , 2014, Brain pathology.

[47]  A. Rademaker,et al.  A phase II trial of PTK787/ZK 222584 in recurrent or progressive radiation and surgery refractory meningiomas , 2014, Journal of Neuro-Oncology.

[48]  Murim Choi,et al.  Genomic Analysis of Non-NF2 Meningiomas Reveals Mutations in TRAF7, KLF4, AKT1, and SMO , 2013, Science.

[49]  Roland Eils,et al.  Secretory meningiomas are defined by combined KLF4 K409Q and TRAF7 mutations , 2013, Acta Neuropathologica.

[50]  D. Eccles,et al.  Loss-of-function mutations in SMARCE1 cause an inherited disorder of multiple spinal meningiomas , 2013, Nature Genetics.

[51]  Robert T. Jones,et al.  Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations , 2013, Nature Genetics.

[52]  M. Chamberlain.  The role of chemotherapy and targeted therapy in the treatment of intracranial meningioma , 2012, Current opinion in oncology.

[53]  S. Spiegl-Kreinecker,et al.  Trabectedin has promising antineoplastic activity in high‐grade meningioma , 2012, Cancer.

[54]  A. B. Grayeli,et al.  Long-term follow-up of 287 meningiomas in neurofibromatosis type 2 patients: clinical, radiological, and molecular features. , 2012, Neuro-oncology.

[55]  U. Haberkorn,et al.  Detection of cranial meningiomas: comparison of 68Ga-DOTATOC PET/CT and contrast-enhanced MRI , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[56]  A. Norden,et al.  Atypical and anaplastic meningiomas treated with bevacizumab , 2012, Journal of Neuro-Oncology.

[57]  R. McLendon,et al.  Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series , 2012, Journal of Neuro-Oncology.

[58]  M. Chamberlain,et al.  Hydroxyurea for recurrent surgery and radiation refractory meningioma: a retrospective case series , 2011, Journal of Neuro-Oncology.

[59]  James J. Evans,et al.  Reirradiation for Recurrent Meningioma , 2010 .

[60]  P. Allavena,et al.  Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells. , 2010, Cancer research.

[61]  I. Steffen,et al.  Potential impact of 68Ga-DOTATOC PET/CT on stereotactic radiotherapy planning of meningiomas , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[62]  Susan M. Chang,et al.  Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08). , 2009, Neuro-oncology.

[63]  M. Chamberlain,et al.  Interferon‐α for recurrent World Health Organization grade 1 intracranial meningiomas , 2008, Cancer.

[64]  M. Chamberlain,et al.  Recurrent meningioma , 2007, Neurology.

[65]  C. Hartmann,et al.  Molecular genetics of meningiomas: from basic research to potential clinical applications. , 2007, Neurosurgery.

[66]  U. Haberkorn,et al.  Improved target volume definition for fractionated stereotactic radiotherapy in patients with intracranial meningiomas by correlation of CT, MRI, and [68Ga]-DOTATOC-PET. , 2006, International journal of radiation oncology, biology, physics.

[67]  S. Groshen,et al.  Salvage chemotherapy With CPT-11 for recurrent meningioma , 2006, Journal of Neuro-Oncology.

[68]  Mahlon D. Johnson,et al.  Mitogenic Signal Transduction Pathways in Meningiomas: Novel Targets for Meningioma Chemotherapy? , 2005, Journal of neuropathology and experimental neurology.

[69]  J. Hoofnagle,et al.  Mechanism of action of interferon and ribavirin in treatment of hepatitis C , 2005, Nature.

[70]  S. Groshen,et al.  Temozolomide for treatment-resistant recurrent meningioma , 2004, Neurology.

[71]  B. Jeremic,et al.  Stereotactic fractionated radiotherapy in patients with optic nerve sheath meningioma. , 2002, International journal of radiation oncology, biology, physics.

[72]  U. Haberkorn,et al.  PET imaging of somatostatin receptors using [68GA]DOTA-D-Phe1-Tyr3-octreotide: first results in patients with meningiomas. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[73]  S. Schulz,et al.  Immunohistochemical determination of five somatostatin receptors in meningioma reveals frequent overexpression of somatostatin receptor subtype sst2A. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[74]  M. Westphal,et al.  Vascular endothelial growth factor, hepatocyte growth factor/scatter factor, basic fibroblast growth factor, and placenta growth factor in human meningiomas and their relation to angiogenesis and malignancy. , 2000, Neurosurgery.

[75]  R. Fahlbusch,et al.  Hydroxyurea for treatment of unresectable and recurrent meningiomas. I. Inhibition of primary human meningioma cells in culture and in meningioma transplants by induction of the apoptotic pathway. , 1997, Journal of neurosurgery.

[76]  G. Cocconi,et al.  Estrogen and progesterone receptors in human meningiomas: biochemical and immunocytochemical evaluation. , 1995, Surgical neurology.

[77]  D. Simpson.  THE RECURRENCE OF INTRACRANIAL MENINGIOMAS AFTER SURGICAL TREATMENT , 1957, Journal of neurology, neurosurgery, and psychiatry.

[78]  M. Hoogeman,et al.  Lower doses to hippocampi and other brain structures for skull-base meningiomas with intensity modulated proton therapy compared to photon therapy. , 2019, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[79]  P. Wen,et al.  Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma. , 2015, Neuro-oncology.

[80]  Susan M. Chang,et al.  Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma , 2009, Journal of Neuro-Oncology.

[81]  O. Chinot,et al.  [Hydroxyurea treatment for unresectable meningioma]. , 2004, Neuro-Chirurgie.

[82]  G. Lapertosa,et al.  Expression of Somatostatin Receptor mRNA in Human Meningiomas and their Implication in in vitro Antiproliferative Activity , 2004, Journal of Neuro-Oncology.

[83]  A. Lomax,et al.  Intensity modulation methods for proton radiotherapy. , 1999, Physics in medicine and biology.

[84]  A. Hagemeijer,et al.  Inhibition of the growth of cultured human meningioma cells by recombinant interferon-alpha. , 1991, European journal of cancer.